NAV

Nefiracetam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Nefiracetam
DrugBank Accession Number
DB13082
Background

Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 246.31
Monoisotopic: 246.136827828
Chemical Formula
C14H18N2O2
Synonyms
  • Nefiracetam
  • Nefiracetamum
External IDs
  • DM 9384
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Nefiracetam.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Nefiracetam.
AcetophenazineThe risk or severity of CNS depression can be increased when Acetophenazine is combined with Nefiracetam.
AgomelatineThe risk or severity of CNS depression can be increased when Agomelatine is combined with Nefiracetam.
AlfentanilThe risk or severity of CNS depression can be increased when Alfentanil is combined with Nefiracetam.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Anilides / m-Xylenes / N-arylamides / Pyrrolidine-2-ones / N-alkylpyrrolidines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
2-pyrrolidone / Alpha-amino acid or derivatives / Anilide / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Hydrocarbon derivative / Lactam
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1JK12GX30N
CAS number
77191-36-7
InChI Key
NGHTXZCKLWZPGK-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
IUPAC Name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
SMILES
CC1=CC=CC(C)=C1NC(=O)CN1CCCC1=O

References

General References
Not Available
PubChem Compound
71157
PubChem Substance
347829207
ChemSpider
64299
ChEBI
135004
ChEMBL
CHEMBL260829
ZINC
ZINC000000003788
Wikipedia
Nefiracetam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.704 mg/mLALOGPS
logP1.62ALOGPS
logP1.58Chemaxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.75Chemaxon
pKa (Strongest Basic)-2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area49.41 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity71.6 m3·mol-1Chemaxon
Polarizability26.6 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-004j-7920010011-f3cb0b77efee19ef8d89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004j-7920010011-f3cb0b77efee19ef8d89
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-7090000000-4ce93bc43384aa07cf68
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dm-2910000000-d6116294e5ef5b6d47e2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0592-3910000000-2f2693947b4163f45a95
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-06fr-4900000000-7b2b980c64e51d36b90b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00xs-9630000000-c68a3b7657af39e9b27e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-8920000000-191bfd8f0b8b9b52801d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-168.101567
predicted
DarkChem Lite v0.1.0
[M-H]-168.788167
predicted
DarkChem Lite v0.1.0
[M-H]-151.49156
predicted
DeepCCS 1.0 (2019)
[M+H]+168.786867
predicted
DarkChem Lite v0.1.0
[M+H]+169.380167
predicted
DarkChem Lite v0.1.0
[M+H]+153.84956
predicted
DeepCCS 1.0 (2019)
[M+Na]+168.033667
predicted
DarkChem Lite v0.1.0
[M+Na]+168.511767
predicted
DarkChem Lite v0.1.0
[M+Na]+160.23122
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 02:49 / Updated at February 21, 2021 18:54